In experimental studies on hypertension and angiotensin II-induced fibrosis, the application of specific antibodies to block IL-17A or IL-17RA resulted in a significant reduction in the fibrotic marker TGF-β1 (74, 75). This evidence concerns the gene IL17A and hypertensive disorder.